"We are committed to conducting ongoing pre-clinical research as we help to further increase physicians' awareness and understanding of the significant role that extracellular matrix materials can have in cardiac applications," commented Beecher Lewis, President and Chief Operating Officer of CorMatrix Cardiovascular. "We will continue pre-clinical trials with our next generation ECM Technology(TM) product and look forward to eventually moving to clinical trials to determine its ability to ultimately reverse the effects of heart failure in humans."
The use of extracellular matrix technology in non-cardiovascular applications has established a significant foothold in soft tissue repair, wound management and orthopedic applications. Since the launch of CorMatrix's ECM for Pericardial Closure, the technology has been used at more than 220 hospitals across the U.S. and has been implanted in more than 9,000 cardiac procedures.
"We have received a tremendous response from the clinical community for our products for pericardial closure and for cardiac tissue repair," said Lewis. "With our next generation ECM Technology, we are pleased to be leading the way toward another important advancement for cardiac surgeons and their patients."
About CorMatrix ECM Technology(TM)
CorMatrix Cardiovascular holds an exclusive license from Purdue
University to research, develop, manufacture and market naturally occurring
ECM products for cardiovascular applications. The company currently has
U.S. FDA clearance and European approval with a CE Mark to market its ECM
Technology as an implant for pericardial closure, FDA clearance in the U.S.
for cardiac tissue repair, and is conducting pre-clinical studies on a
number of cardiovascular applications including an
|SOURCE CorMatrix Cardiovascular, Inc.|
Copyright©2008 PR Newswire.
All rights reserved